Resource Type

Journal Article 1421

Conference Videos 60

Conference Topics 1

Year

2024 5

2023 111

2022 139

2021 155

2020 104

2019 103

2018 88

2017 80

2016 56

2015 73

2014 59

2013 53

2012 41

2011 50

2010 46

2009 70

2008 44

2007 55

2006 13

2005 12

open ︾

Keywords

high-quality development 16

fuel cell 13

immunotherapy 8

high speed railway 7

temperature 7

control 6

innovation 6

solar cell 6

durability 5

hematopoietic stem cell transplantation 5

hepatocellular carcinoma 5

hydrogen energy 5

prognosis 5

stem cell 5

COVID-19 4

High-throughput sequencing 4

SARS-CoV-2 4

cell proliferation 4

development 4

open ︾

Search scope:

排序： Display mode:

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 69-82 doi: 10.1007/s11684-018-0677-1

Abstract:

Cytokine-activated T cells (CATs) can be easily expanded and are widely applied to cancer immunotherapyThe low-efficacy problem can be resolved using T cell antigen receptor-engineered CAT (TCR-CAT).Herein, we demonstrate that NY-ESO-1157–165 HLA-A*02:01-specific high-affinity TCR (HAT)-transducedFurthermore, the high-affinity TCR-CATs delivered significantly better activation and cytotoxicity than">g and granzyme B production and in vitro cancer cell killing ability.

Keywords： cytokine-activated T cells     high-affinity T cell receptor     cancer immunotherapy     TCR-CAT    

HTML PDF Collect

PtHAK5, a candidate for mediating high-affinity K

Haili YANG, Weidan ZHANG, Weiwei CHAI, Wenying WANG, Li GAO, Jing ZHANG, Yongping WANG, Suo-Min WANG

Frontiers of Agricultural Science and Engineering 2018, Volume 5, Issue 1,   Pages 108-117 doi: 10.15302/J-FASE-2018200

Abstract: results showed PtHAK5 consisted of 784 amino acids and shared over 80% homology with the identified high-affinityIn conclusion, PtHAK5 is a candidate for mediating high-affinity K uptake under low K conditions.

Keywords： K+ uptake     PtHAK5     Puccinellia tenuiflora     yeast complementation    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellRelapse remains the main cause of treatment failure, especially for patients with intermediate or highAllogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemiaAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remainsIn this review, we focus on the most recent and promising advances in CAR T therapies for AML.

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients.achieved complete remission after receiving the CD19 CAR-T cell therapy.cell therapy.Therefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy withthe toxicity in patients with lymphoma after the CAR-T cell therapy.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cellcells, leading to CAR-T cell therapy failure and disease progression in DLBCL.Immunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansioncell therapy.

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellA single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of Tbearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cellTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatment

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract: In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future.Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in variouscell lines.The culture conditions for the cell line, including cell density, temperature, and culture medium were

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-HodgkinHowever, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especiallypatient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cellCAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptorT cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: Factors associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T (CAR-T) cell immunotherapy for relapsed or refractory non-Hodgkin lymphoma (r/r NHL) have not been wellsurvival (OS), and progression-free survival (PFS) in patients with r/r NHL treated with anti-CD19 CAR-Tcell therapy.Thus, anti-CD19 CAR-T cell therapy may improve the prognosis of patients with BM infiltration.

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkin    

HTML PDF Collect

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Frontiers of Medicine 2012, Volume 6, Issue 4,   Pages 416-420 doi: 10.1007/s11684-012-0224-4

Abstract:

Acute lymphoblastic leukemia includes T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acutephenotype that resembles early T-cell precursor, which confers a much poorer prognosis than any otherform of T-ALL.This novel subtype of T-ALL was called early T-cell precursor acute lymphoblastic leukemia (ETP-ALL).Our findings demonstrate that early T-cell precursor leukemia is a very high-risk subtype of acute lymphoblastic

Keywords： acute lymphoblastic leukemia     early T precursor     prognosis    

HTML PDF Collect

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 3-11 doi: 10.1007/s11684-019-0684-x

Abstract: This malignancy is associated with poor prognosis and high mortality.The antitumor activities of adoptive cell transfer therapy (ACT), such as strategies based on tumor-infiltratingCurrently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughshematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cellThe clinical results of CAR-T immunotherapy for HCC that could be obtained at present are limited.

Keywords： adoptive cell transfer therapy     hepatocellular carcinoma     T cell     chimeric antigen receptor     immunotherapy    

HTML PDF Collect

High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library Article

Hao Liu, Chunxia Qiao, Naijing Hu, Zhihong Wang, Jing Wang, Jiannan Feng, Beifen Shen, Yuanfang Ma, Longlong Luo

Engineering 2021, Volume 7, Issue 11,   Pages 1557-1565 doi: 10.1016/j.eng.2020.11.011

Abstract:

Immunotherapy with anti-programmed cell death protein-1 (PD-1)/programmed cell death ligandThe PD-1/PD-L1 pathway inhibits T cell activation in the micro-environment, making it anAfter three rounds of cell sorting, the decoy PD-1 mutant 463, which presented a higher affinity thanWT PD-1 to the PD-L1 (the affinity has increased by almost three orders of magnitude) was screened outThe 463 decoy mutant reversed the inhibitory function of PD-1 in T cell activation; furthermore, 10 

Keywords： Decoy PD-1     PD-L1     Mammalian cell library     Epitope-oriented    

HTML PDF Collect

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 322-338 doi: 10.1007/s11684-021-0901-2

Abstract: To date, six chimeric antigen receptor T cell (CAR-T) therapies have been permitted for the treatmentHowever, several clinical trials of solid tumor CAR-T therapies were prematurely terminated, or theyglycosylated glycoforms of tumor-associated antigens can also minimize the off-tumor effects of CAR-TTn, T, and sialyl-Tn antigens have been reported to be involved in tumor progression and metastasis,how underglycosylated antigens emerge and then detail the latest advances in the development of CAR-T-based

Keywords： cancer immunotherapy     chimeric antigen receptor     solid tumors     tumor-associated antigen     glycosylation     O-glycans     adoptive cell therapy    

HTML PDF Collect

Engineered T Cell Therapies from a Drug Development Viewpoint Review

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Engineering 2019, Volume 5, Issue 1,   Pages 140-149 doi: 10.1016/j.eng.2018.11.010

Abstract: For example, T cells can be genetically modified to express chimeric antigen receptors (CARs), endowingAnti-CD19 chimeric antigen receptor T cells (CART19) have demonstrated a remarkable degree of clinicalWe believe that the success of CART19 will lead to the development of other engineered T cell therapies

Keywords： Engineered T cell therapies     Chimeric antigen receptor     Drug development process     Biomarkers     CAR19    

HTML PDF Collect

Deubiquitinases as pivotal regulators of T cell functions

Xiao-Dong Yang, Shao-Cong Sun

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 451-462 doi: 10.1007/s11684-018-0651-y

Abstract:

T cells efficiently respond to foreign antigens to mediate immune responses against infections butDefect in T cell activation is associated with severe immune deficiencies, whereas aberrant T cell activationAn emerging mechanism that regulates T cell activation and tolerance is ubiquitination, a reversibleIt is now well recognized that DUBs are crucial regulators of T cell responses and serve as potentialThis review will discuss the recent progresses regarding the functions of DUBs in T cells.

Keywords： deubiquitinase     ubiquitination     T cell activation     T cell differentiation     T cell tolerance    

HTML PDF Collect

Title Author Date Type Operation

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

Synat Kang, Yanyan Li, Yifeng Bao, Yi Li

Journal Article

PtHAK5, a candidate for mediating high-affinity K

Haili YANG, Weidan ZHANG, Weiwei CHAI, Wenying WANG, Li GAO, Jing ZHANG, Yongping WANG, Suo-Min WANG

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptorT cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen

Journal Article

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Journal Article

High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library

Hao Liu, Chunxia Qiao, Naijing Hu, Zhihong Wang, Jing Wang, Jiannan Feng, Beifen Shen, Yuanfang Ma, Longlong Luo

Journal Article

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Journal Article

Engineered T Cell Therapies from a Drug Development Viewpoint

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Journal Article

Deubiquitinases as pivotal regulators of T cell functions

Xiao-Dong Yang, Shao-Cong Sun

Journal Article